Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04545749
Recruitment Status : Recruiting
First Posted : September 11, 2020
Last Update Posted : September 29, 2020
Sponsor:
Collaborator:
COVAXX
Information provided by (Responsible Party):
United Biomedical Inc., Asia

Brief Summary:
This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults, aged from 20 to 55 years old.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: UB-612 Phase 1

Detailed Description:
This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults. Up to 60 subjects (20 subjects per group) will be enrolled into this study. Subjects in each group will be enrolled to receive two doses of UB-612 vaccine at 28-day interval (Day 0 and Day 28).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers
Actual Study Start Date : September 25, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : August 31, 2021

Arm Intervention/treatment
Experimental: Group A (Low dose)
20 subjects will be enrolled to receive low dose of UB-612 vaccine.
Biological: UB-612
UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine developed by UBI/UBIA Group. UB-612 also incorporates a Th/CTL epitope peptide pool, selected from the immunologically advantageous M, S2 and N sites on virus, that could bind to human MHC-I and MHC-II to activate T cells.

Experimental: Group B (Medium dose)
20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
Biological: UB-612
UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine developed by UBI/UBIA Group. UB-612 also incorporates a Th/CTL epitope peptide pool, selected from the immunologically advantageous M, S2 and N sites on virus, that could bind to human MHC-I and MHC-II to activate T cells.

Experimental: Group C (High dose)
20 subjects will be enrolled to receive high dose of UB-612 vaccine.
Biological: UB-612
UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine developed by UBI/UBIA Group. UB-612 also incorporates a Th/CTL epitope peptide pool, selected from the immunologically advantageous M, S2 and N sites on virus, that could bind to human MHC-I and MHC-II to activate T cells.




Primary Outcome Measures :
  1. Safety of UB-612 vaccine [ Time Frame: 7 days following vaccination ]
    1. Occurrence of adverse reactions within 7 days after vaccination
    2. Percentage of subjects with ≥ Grade 3 adverse events within 7 days after vaccination


Secondary Outcome Measures :
  1. Safety [ Time Frame: Day 0 to Day 56 ]
    1. Occurrence of adverse events (AEs) till Day 56
    2. Occurrence of serious adverse events (SAEs) till Day 56

  2. Safety [ Time Frame: Day 29 to Day 196 ]
    Occurrence of serious adverse events during the whole follow-up period

  3. Safety [ Time Frame: Day 0 to Day 196 ]
    Occurrence of adverse events of special interest during the study period

  4. Immunogenicity [ Time Frame: Day 14, 28, 42, 56, 112, and 196 ]
    Geometric mean titer (GMT) of antigen-specific antibody (Anti-S1-RBD)

  5. Immunogenicity [ Time Frame: Day 14, 28, 42, 56, 112, and 196 ]
    Seroconversion rate (SCR) of antigen-specific antibody (Anti-S1-RBD)

  6. Immunogenicity [ Time Frame: Day 14, 28, 42, 56, 112, and 196 ]
    Geometric mean fold increase of antigen-specific antibody (Anti-S1-RBD)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment.
  2. Women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination.
  3. Able to understand the content and possible risks of informed consent and willing to sign the Informed Consent Form (ICF).
  4. Able to understand and agrees to comply with all study procedures and be available for all study visits.
  5. Negative serological test for Hepatitis B surface antigen (HBsAg), HCV RNA and HIV antibody screening.
  6. Negative in serum antibodies (IgG) against SARS-CoV-2 ELISA.
  7. Negative result of RT-PCR screening of nasopharyngeal or throat swabs for SARS-CoV-2.
  8. Ear temperature ≤ 38.0°C.
  9. The body mass index (BMI) of 18-30 kg/m2, inclusive, at screening.
  10. Indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators.
  11. Judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ECG, vital signs, and clinical laboratory tests performed at screening.

Exclusion Criteria:

  1. History of anaphylaxis, urticarial, or other significant adverse reaction requiring medical intervention after receipt of a vaccine.
  2. Female who is pregnant or positive in pregnancy test at screening or just prior to each vaccination administration.
  3. Female who is breast-feeding or plans to breastfeed from the time of the first vaccination through 60 days after the last vaccination.
  4. Any acute illness, as determined by the study investigator 3 days before first vaccination.
  5. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  6. Known history of SARS or MERS.
  7. Previous exposure to SARS-CoV-2 or receipt of an investigational vaccine product for the prevention of COVID-19, MERS or SARS.
  8. Subjects who take part in another clinical study within 12 weeks prior to the day of informed consent.
  9. With certain underlying medical conditions which are at increased risk for severe illness from COVID-19.
  10. Congenital or acquired angioedema.
  11. Immune deficiency/disorder, whether due to genetic defect, immunodeficiency disease or immunosuppressive therapy.
  12. Platelet disorder or other bleeding disorder may cause injection contraindication.
  13. Prior chronic administration of immunosuppressant or corticosteroids, cytotoxic treatment in last 6 months before first vaccination.
  14. Prior administration of immunoglobulins and/or any blood products in last 4 months before first vaccination.
  15. Prior administration of attenuated, nucleic acid (mRNA or DNA) or vectored vaccines in last 1 month before first vaccination or expectation of such vaccines in the month after the second vaccination.
  16. Prior administration of subunit vaccine or inactivated vaccine in last 14 days before first vaccination or expectation of receipt of such vaccines in the 14 days after the second vaccination.
  17. Current anti-tuberculosis (TB) therapy or history of TB.
  18. Alcoholism or substance abuser.
  19. History of malignancy within 5 years prior to screening visit, except basal cell carcinoma of the skin and cervical carcinoma in situ.
  20. Any medical disease or condition that, in the opinion of the study investigator, may confound the results of the study or pose an additional risk to the subjects by their participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545749


Contacts
Layout table for location contacts
Contact: Joanna Hung +886-3-657-8861 ext 5297 joanna.hung@ubiasia.com.tw

Locations
Layout table for location information
Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan, 404
Contact: Kao-Pin Hwang, M.D., Ph.D.         
Principal Investigator: Kao-Pin Hwang, M.D., Ph.D.         
Sub-Investigator: Po-Chang Lin, M.D.         
Sub-Investigator: Wen-Yuan Lin, M.D., Ph.D.         
Sponsors and Collaborators
United Biomedical Inc., Asia
COVAXX
Investigators
Layout table for investigator information
Study Chair: Chang-Yi Wang, Ph.D. United Biomedical
Layout table for additonal information
Responsible Party: United Biomedical Inc., Asia
ClinicalTrials.gov Identifier: NCT04545749    
Other Study ID Numbers: V-122
First Posted: September 11, 2020    Key Record Dates
Last Update Posted: September 29, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No